File photo shows a staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd., in Beijing. (Xinhua File/Zhang Yuwei)
A phase 2 trial of a COVID-19 vaccine candidate in China has found that the vaccine is safe and induces an immune response, according to a new study published Monday in medical journal The Lancet.
版权及免责声明：凡本网所属版权作品，转载时须获得授权并注明来源“东盟评论社”，违者本网将保留追究其相关法律责任的权力。凡转载文章，不代表本网观点和立场。版权事宜请联系：。
新技术迸发“新质生产力” 第二十六届高交会意向成交金额突破1200亿
